Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 4/20 | 0.55 |
| ▸ | CNR2 | P34972 | 4/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915736 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL3168889 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL4557099 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| Hexadecanoic Acid Allylamide SCHEMBL4914176 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL30763460 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL8251669 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL4013783 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL4014444 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL699154 | 1.00 | FAAH (1.00) | FAAHTSHRSMN1; SMN2MAPTDNM1 | |
| SCHEMBL28373906 | 0.98 | FAAH (0.96) | FAAHTSHRSMN1; SMN2MAPTDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022084351-A1 | CROSS-LINKABLE ALLYLAMIDO POLYMERS | UNIVERSITEIT GENT (BE) | 2022-04-28 | — | — | WO | disclosed |
| US-7154004-B2 | Catalytic transamidation and amide metathesis under moderate conditions | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20040230078-A1 | Catalytic transamidation and amide metathesis under moderate conditions | NATIONAL SCIENCE FOUNDATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230078-A1 | Catalytic transamidation and amide metathesis under moderate conditions | NAAA, NIT2, NAT10 | FAAH 43/4885TSHR 994/4885SMN1; SMN2 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.